logo

COGT

Cogent Biosciences·NASDAQ
--
--(--)
--
--(--)
4.25 / 10
Netural

The company's fundamental score is 4.2/10, indicating average health. Key positives include a strong 92.79% year-over-year operating revenue growth and a solid 15.51% interest-coverage ratio, which support operational efficiency and debt sustainability. However, factors like inventory turnover (47.88) and net profit margin (100%) are offset by negative asset and cash market-value gaps (-0.51 and -0.07), while revenue and profit gaps (-0.26 and 0.47) show mixed performance. Overall, fundamentals are balanced but not exceptional, warranting cautious optimism.

Fundamental(4.25)SentimentTechnical

Analysis Checks(10/10)

Revenue-MV
Value-0.26
Score3/3
Weight21.62%
1M Return11.03%
Total operating revenue (YoY growth rate %)
Value78.62
Score3/3
Weight1.39%
1M Return0.88%
Inventory turnover ratio
Value47.88
Score2/3
Weight-1.80%
1M Return-1.23%
Profit-MV
Value0.47
Score2/3
Weight17.35%
1M Return8.99%
PB-ROE
Value2.79
Score2/3
Weight23.23%
1M Return10.90%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.51
Score2/3
Weight-1.87%
1M Return-1.25%
Operating revenue (YoY growth rate %)
Value92.79
Score2/3
Weight0.16%
1M Return0.10%
Asset-MV
Value-0.51
Score2/3
Weight24.74%
1M Return12.15%
Net profit / Total profit (%)
Value100.00
Score2/3
Weight-1.48%
1M Return-0.98%
Cash-MV
Value-0.07
Score2/3
Weight16.66%
1M Return8.80%
Is COGT fundamentally strong?
  • COGT scores 4.25/10 on fundamentals and holds a Fair valuation at present. Backed by its -81.05% ROE, 0.00% net margin, -19.15 P/E ratio, 18.64 P/B ratio, and -28.93% earnings growth, these metrics solidify its Netural investment rating.